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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2015, KaohsiuAbstract Vitiligo is a refractory skin disease. To investigate the risk factors and treatment
responses of patients with vitiligo in Japan, we recorded and analyzed the details of 713 viti-
ligo patients (comorbidity, treatment responses, family history, age, and sex) who visited the
dermatology clinic of the Nagoya City University Hospital, Nagoya, Japan between January
2004 and August 2010 (mean age, 35.2 years; 302 men, 411 women) using logistic regression
analysis. The results are expressed as odds ratios (OR) with 95% confidence interval (CI). Pa-
tients were diagnosed with vitiligo [nZ 644; 338 generalized type (47.4%), 170 segmental type
(23.8%), and 136 localized type (19.1%)], nevus depigmentosus (n Z 53, 7.4%), halo nevus
(n Z 14, 2.0%), and hypomelanosis of Ito (n Z 2, 0.3%). For generalized and localized types,
none of the analyzed factors were statistically significant. For the segmental type, antinuclear
antibody (ORZ 1.005; 95% CI, 1.00e1.01; p < 0.05) and onset age < 14 years were the signif-
icant factors in patients between 15 years and 29 years (OR Z 0.246; 95% CI, 0.113e0.538;
p < 0.001), 30e54 years (OR Z 0.0419; 95% CI, 0.0133e0.132; p < 0.001), and >55 years
(OR Z 0.0171; 95% CI, 0.00333e0.0879; p < 0.001). The treatment response rates for
narrow-band UV-B, topical vitamin D3, and punch graft (1 mm minigraft) were, respectively,
as follows: (1) generalized type: 46.3%, 21.1%, and 38.9%; (2) segmental type: 20.3%, 29.0%,
and 77.3%; and (3) localized type: 29.2%, 54.8%, and 73.3%. We report the comorbidities and
efficacy rates of these treatments. The response data for these treatments, in particular,
would be of assistance to the previous explanations, because there were only a few reportseclare no conflicts of interest.
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ya-cu.ac.jp (H. Kato).
5.02.003
ng Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
Risk factors and treatment of vitiligo 261Table 1 Patients’ profile.a
Type (cases)
Generalized (338)
Segmental (170)
Localized (136)
a A total of 644 vitiligo patients wh
study. There was a significant differon the response data for these treatments. The appropriate treatment should be selected de-
pending on the type of vitiligo.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Vitiligo is a refractory skin disease in which risk factors and
treatment modalities are not yet established. There are
three clinical types of vitiligo: (1) generalized type, which
spreads widely over the body; (2) segmental type, which
spreads along the course of a nerve; and (3) localized type,
which is unclassifiable and can develop into either gener-
alized or segmental type in the future [1]. The efficacy of
treatment was different for each type [2]. Some large-scale
studies were conducted in Brazilian and Chinese pop-
ulations [3,4]. In these studies, the risk factors of vitiligo
included thyroid dysfunction and type 1 diabetes mellitus.
In Japan, Narita et al [5] reported on the comorbidities and
family history 133 vitiligo patients. Zaima and Koga [1],
meanwhile, conducted a long-term follow-up of about 44
localized vitiligo cases. In this study, the data of >700 pa-
tients were collected and analyzed, although there was no
such large-scale study in Japan. To investigate the risk
factors and treatment responses of patients with vitiligo in
Japan, we analyzed the data of vitiligo patients who visited
our dermatology clinic (Nagoya City University Hospital,
Nagoya, Japan).
Patients and methods
A total of 713 patients of Japanese origin with a chief
complaint of depigmentation (mean age, 35.2 years; 302
men, 411 women) were recruited for the study. Of these, 69
patients were excluded because they were diagnosed to
have other depigmented diseases [nevus depigmentosus
(n Z 53, 7.4%), halo nevus (n Z 14, 2.0%), and hypomela-
nosis of Ito (n Z 2, 0.3%)]. Therefore, we analyzed the
details of 644 vitiligo patients [generalized type, 338
(47.4%); segmental type, 170 (23.8%); localized type, 136
(19.1%)], including their background, comorbidities, treat-
ment responses, family history, age, and sex (Table1).
Furthermore, multivariable logistic regression analysis
comparing segmental vitiligo against other types was per-
formed. As an evaluation for narrow-band UV-B therapy and
topical vitamin D3 therapy, when the pigmentation wasMen/women (cases)
154/184
77/95
50/84
o visited Nagoya City University h
ence between generalized type afound in the treatment area, the case was evaluated as
effective; if not, the case was considered not effective.
The accumulative dose of narrow-band UV-B was between
5.5 J/cm2 and 25 J/cm2. The 1-mm minigraft therapy was
one of the surgical treatment options for vitiligo. The skin
donor site was the abdomen, and full-thickness grafts were
obtained using a 1-mm punch (Kai Industry, Seki, Japan)
following the administration of local anesthesia or full
anesthesia. Using the 1-mm punch, holes were made in the
vitiligo lesions with 3e5 mm between them. After hemo-
stasis, the grafts were implanted into the holes. Overall,
3e200 grafts were done for each case. In the 1-mm mini-
graft therapy, when the stable pigmentation was found
around the transplanted point, that case was evaluated as
effective; if not, that case was evaluated as not effective.
We determined the effect of topical therapy after 6 months
and that of narrow-band UV-B after 30 irradiations. The
effect of 1-mm minigraft therapy was determined after 1
month. A total of 323 cases (head and neck, 148 cases;
body, 144 cases; extremities, 31 cases) treated using at
least one of these methods were analyzed based on their
location. All treatment methods were explained to the
patients, who then made their own choice. Patients who
had vitiligos with large surface areas tended to select
narrow-band UV-B. By contrast, patients with small vitiligo
lesions tended to choose topical therapy. Surgical treat-
ment was mostly selected by patients who were unre-
sponsive to less invasive therapies. Statistical analyses
were performed using the Pharmaco Analyst II software
(Human Life, Tokyo, Japan) and Excel (Microsoft, Redmond,
WA, USA).Results
Table 2 shows the comorbidities of each type of vitiligo.
Overall, 7.69% of patients with generalized-type vitiligos
experienced complications (i.e., thyroid dysfunction), as
compared to only 0.59% for those with the segmental type
(p < 0.01, Chi-square test). Furthermore, 3.55% of patients
with generalized-type vitiligos were complicated with car-
cinoma, as compared to only 0.59% for those with theAge of onset (y) Disease duration (y)
38.45  22.38 7.080  9.996
11.09  12.03 3.360  6.243
32.71  24.53 3.836  8.078
ospital between April 2004 and August 2010 were analyzed in this
nd segmental type.
Table 2 Comorbidities.
Type (cases) Carcinoma cases (%) Atopic dermatitis
cases (%)
Alopecia
cases (%)
Uticaria
cases (%)
Thyroid dysfunction
cases (%)
Generalized (338) 12 (3.55)* 13 (3.85) 4 (1.18) 3 (0.89) 26 (7.69)
Segmental (170) 1 (0.59) 3 (1.76) 1 (0.59) 1 (0.59) 1 (0.59)**
Localized (136) 0 (0) 3 (2.21) 0 (0) 0 (0) 8 (5.88)
7.69% of generalized type vitiligo patients had thyroid dysfunction. In contrast, 0.59% of segmental type vitiligo patients had it (*p<0.05,
**p<0.01, Chai-square test).
Also 3.55% of patients were complicated with Carcinoma, whereas were only 0.59% with the segmental type (*p<0.05, **p<0.01,
Chi-square test).
Table 3 Family history.a
Type (no. of cases) Family history cases (%)
Generalized (338) 12 (3.55)
Segmental (170) 1 (0.59)
Localized (136) 2 (0.59)
a Overall, 3.55% of generalized type vilitigo patients had a
family history of their condition. By contrast, few patients who
had segmental and localized types of vitiligo had it. There was
no significant difference in each group (Chi-square test).
262 R. Ohguchi et al.segmental type (p < 0.05, Chi-square test). In addition,
3.55% of generalized type had a family history of their
condition, as compared to only 0.59% of segmental type
(Table 3) . However, this difference was not statistically
significant.
Multivariable logistic regression analysis was performed
for each type of vitiligo against other types. For generalized
and localized types, none of the analyzed factors were
statistically significant. For the segmental type, antinuclear
antibody (ANA) [odds ratio (OR) Z 1.005; 95% confidence
interval (CI), 1.00e1.01; p < 0.05] and onset age < 14 years
were significant factors in patients who were 15e29 years
old (OR Z 0.246; 95% CI, 0.113e0.538; p < 0.001), 30e54
years old (ORZ 0.0419; 95% CI, 0.0133e0.132; p < 0.001),
and >55 years (OR Z 0.0171; 95% CI, 0.00333e0.0879;
p < 0.001) (Table 4). The individuals whose condition was
complicated by thyroid dysfunction were older than the
others (Fig. 1). The data on the treatment response of eachTable 4 Logistic regression.a
Characteristic
Age (664 cases) 15e29 y
30e54 y
>55 y
Sex (664 cases) Men
ANA (336 cases) 10 units
TSH (344 cases) 1 unit
FT3 (340 cases) 1 unit
FT4 (340 cases) 1 unit
Having a carcinoma (664 cases)
Having a thyroid dysfunction (664 cases)
a Multivariable logistic regression was performed in segmental vitil
antibodies (higher) were risk factors of the segmental type in vitiligo
cases is as follows: <14 years old, 169 cases; 15e29 years old, 129 catype of vitiligo are shown in Fig. 2. Narrow-band UV-B was
significantly effective for the generalized type and the
localized type (p < 0.05, Chi-square test). The treatment
response rate was 46.3% for the generalized type, 20.3% for
the segmental type, and 29.2% for the localized type. The
1-mm minigraft was significantly effective for the
segmental type and the localized type (p < 0.01, Chi-
square test). The treatment response rate was 38.9% for
the generalized type, 77.3% for the segmental type, and
73.3% for the localized type. Topical vitamin D3 therapy was
significantly effective for the localized type (p < 0.05, Chi-
square test). The treatment response rate was 21.1% for
the generalized type, 29.0% for the segmental type, and
54.8% for the localized type. Vitiligo lesions located in the
head, neck, and body were treated more effectively than
those located in the extremities (**p < 0.01, Chi-square
test; Table 5).Discussion
Pathophysiologically, the detailed mechanisms of vitiligos
remain unclear. In the generalized type, there were many
reports relating to autoimmune diseases such as thyroid
dysfunction, type 1 diabetes mellitus, Addison disease, and
alopecia areata [6]. The antimelanocyte antibodies that
destroyed melanocytes were identified in many patients in
the 1990s [7]. Jin et al [8] highlighted NALP1 gene poly-
morphism in vitiligo patients using the single-nucleotide
polymorphism method [8]. They reported that generalizedOdds ratio 95% confidence interval p
0.246 0.103e0.538 <0.001**
0.042 0.113e0.132 <0.001**
0.017 0.003e0.088 <0.001**
0.657 0.335e1.291 0.223
1.005 1.001e1.010 0.039*
1.001 0.724e1.385 0.994
1.114 0.744e1.735 0.554
0.988 0.868e1.124 0.853
0.312 0.026e3.767 0.595
0.076 0.003e2.167 0.131
igo against other types of vitiligo. Age (younger) and antinuclear
vulgaris (*p<0.05, **p<0.01). The breakdown of the number of
ses; 30e54 years old, 157 cases; and >55 years old, 189 cases.
Figure 1. Analysis between age and thyroid dysfunction.
Patients with thyroid dysfunction were older than the other
vitiligo patients. This is one of the reasons why no significant
difference was found in the logistic regression analysis.
Risk factors and treatment of vitiligo 263vitiligo was correlated with thyroid disease, autoimmune
diabetes, and rheumatism in a statistically significant level.
It was well known that CD8-positive T cells damaged me-
lanocytes directly [9]. Lili et al [10] reported that an
imbalance between CD8-positive T cells and regulatory T
cell existed in patients with vitiligo [10]. In vitiligo, Th17
positive cells infiltrated the upper dermis, suggesting that
cytokines associated with Th17 such as IL-1a, TNF-a, andFigure 2. Treatment response. The dark bar denotes effective
evaluation for narrow-band UV-B therapy and topical vitamin D3 the
that case was evaluated as effective; if not, that case was deemed
pigmentation was found around the transplanted point, that case w
effective. (A) Narrow-band UV-B had a good outcome in generalized
minigraft, by contrast, had a good outcome in segmental and local
elicited a good response in localized type (*p < 0.05, Chi-square tIL17 A play a role in the dysregulation of melanocytes [11].
In addition, nitrogen monoxide and hydrogen peroxide as
oxidant stress increased in vitiligo lesions [12]. By contrast,
antioxidants such as catalase, ubiquinol, and vitamin E
decreased in lesions. The failure of the autonomic balance
of the lesion contributed to the risk of segmental vitiligo
[13].
We conducted a large retrospective study in Japan.
Unexpectedly, thyroid disease and malignant tumor did not
prove to be related to any type of vitiligo in terms of
complications. Younger age of onset and higher ANA were
noted in segmental vitiligo, as compared with generalized
vitiligo. ANA became positive in healthy controls at a con-
stant rate. Overall, 8.3% of healthy adults had a titer of
>1:160. By contrast, in children, 15.6% had a titer of
>1:160. One of the reasons for the high titer of ANA might
be attributed to the population of children in our segmental
cases [14,15]. Age of onset occurred later in patients who
had thyroid disease compared with those who did not have
this condition, a factor that might have played a role in the
result of the multivariable logistic regression analysis.
Narrow-band UV-B was effective for generalized vitiligos.
There are many reports about the use of narrow-band UV-B
for vitiligo, although its mechanism of action has not been
made clear [16,17]. Dong et al [18] reported that narrow-
band UV-B differentiated hair follicle-derived neural crest
stem cells into melanocyte lineage. By contrast, 1-mm
minigraft therapy was effective for segmental and local-
ized vitiligos, suggesting that the mechanism was different
between segmental vitiligo and generalized vitiligo [19].cases and sickly gray bar denotes not effective cases. As an
rapy, when the pigmentation was found in the treatment area,
not effective. For the 1-mm minigraft therapy, when the stable
as evaluated as effective; if not, that case was evaluated as not
and localized types (*p < 0.05, Chi-square test). (B) The 1-mm
ized types (**p < 0.01, Chi-square test). (C) Topical vitamin D3
est).
Table 5 Successful cases and locationdvitiligo cases
located in the head, neck, and body were more effectively
treated than those located in extremities.
Location (cases) Successful cases (%)
Head and neck (148) 59.5
Body (144) 56.9
Extremity (31) 22.6*
*p < 0.01, Chi-square test.
264 R. Ohguchi et al.Surgical treatment should be selected for cases where the
Koebner phenomenon does not occur, and no progress has
been made for more than a year [2]. Topical vitamin D
therapy was effective for localized vitiligos. Goktas et al
[20] reported that the combined approach of narrow-band
UV-B and topical vitamin D therapy was effective for
generalized vitiligos [20]. The combination of narrow-band
UV-B and topical vitamin D therapy decreased the number
of Langerhans cells and increased regulatory T cells, sug-
gesting that this combination therapy induced immune
suppression [21]. Based on the results, narrow-band UV-B is
recommended for the generalized type of vitiligo, and 1-
mm minigraft is recommended for the segmental and
localized types. For some cases, especially localized types,
it may be appropriate to use topical vitamin D3 therapy. Age
of onset and some laboratory findings can be helpful when
making a diagnosis and selecting an appropriate therapy. As
time goes on, the accumulation of data from case reports
and large-scale analyses is expected to lead to the discov-
ery of a better therapy. For this retrospective study, how-
ever, no clear criterion has been established for the choice
of treatment. Therefore, a prospective study is necessary
to assess the efficacy of each specific treatment.
In conclusion, we reported on the comorbidities and
effective treatment rates of a large-scale study for vitiligo
patients. In particular, the response data for these treat-
ments will be helpful to previous explanations because
there have only been very few reports about the response
data for such treatments. The appropriate treatment
should be selected depending on the type of vitiligo.
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